Michael  Goettler net worth and biography

Michael Goettler Biography and Net Worth

CEO of Viatris
Michael Goettler is the chief executive officer of Viatris, with responsibility for the execution of the company’s strategy and a focus on leveraging Viatris' enhanced commercial capabilities in China and other key markets. He also serves on the board of directors.

Before joining Viatris, Goettler was the group president of Pfizer’s Upjohn division, the company’s off-patent and generics business, and a member of Pfizer’s executive leadership team. Goettler has extensive commercial leadership experience and has lived and worked in multiple markets in both Asia/Pacific and Europe. Before becoming Upjohn's group president in 2018, he served as the global president of Pfizer Inflammation & Immunology, overseeing a portfolio of inline medicines as well as late-stage, early development and research strategy, and programs spanning rheumatology, dermatology and gastroenterology.

Goettler held several other previous roles at Pfizer, including global president, Rare Disease Business, where he initiated the company’s commercial move into gene therapy. He also served as senior vice president, global commercial officer and president Europe, Specialty Care. Goettler joined Pfizer in 2009 as part of the Wyeth acquisition and held a number of senior leadership roles at both Wyeth and Pfizer.

Prior to Wyeth, Goettler held a variety of senior positions at Sanofi Aventis in the U.S. and Japan, where he focused on business development, eBusiness and global marketing. Goettler began his career at Hoechst in Germany and became executive vice president and chief executive officer of Hoechst Marion Roussel Korea.

Goettler, a native of Germany, earned an M.B.A. at the University of Texas at Austin after graduating from the Koblenz School of Corporate Management in Germany.

How do I contact Michael Goettler?

The corporate mailing address for Mr. Goettler and other Viatris executives is 1000 MYLAN BOULEVARD, CANONSBURG PA, 15317. Viatris can also be reached via phone at (724) 514-1800 and via email at [email protected]. Learn More on Michael Goettler's contact information.

Has Michael Goettler been buying or selling shares of Viatris?

Michael Goettler has not been actively trading shares of Viatris during the past quarter. Most recently, on Tuesday, March 15th, Michael Goettler bought 50,352 shares of Viatris stock. The stock was acquired at an average cost of $9.87 per share, with a total value of $496,974.24. Learn More on Michael Goettler's trading history.

Who are Viatris' active insiders?

Viatris' insider roster includes W. Cornwell (Director), Robert Coury (Chairman), Michael Goettler (CEO), James Kilts (Director), Menassie Taddese (insider), and Pauline van der Meer Morh (Director). Learn More on Viatris' active insiders.

Are insiders buying or selling shares of Viatris?

During the last twelve months, insiders at the sold shares 8 times. They sold a total of 325,290 shares worth more than $3,901,932.18. The most recent insider tranaction occured on March, 13th when insider Anthony Mauro sold 250,000 shares worth more than $3,022,500.00. Insiders at Viatris own 0.3% of the company. Learn More about insider trades at Viatris.

Information on this page was last updated on 3/13/2024.

Michael Goettler Insider Trading History at Viatris

Transaction DateBuy/SellNumber of SharesAverage Share PriceTotal TransactionShares Held After TransactionDetails
3/15/2022Buy50,352$9.87$496,974.24View SEC Filing Icon  
See Full Table

Michael Goettler Buying and Selling Activity at Viatris

This chart shows Michael Goettler's buying and selling at Viatris by year and by quarter.

Skip ChartChart Data in Insider Trading History Table

Viatris Company Overview

Viatris logo
Viatris Inc. operates as a healthcare company worldwide. The company operates in four segments: Developed Markets, Greater China, JANZ, and Emerging Markets. It offers prescription brand drugs, generic drugs, complex generic drugs, biosimilars, and active pharmaceutical ingredients (APIs). The company offers drugs in various therapeutic areas, including noncommunicable and infectious diseases; biosimilars in the areas of oncology, immunology, endocrinology, ophthalmology, and dermatology; and APIs for antibacterial, central nervous system agents, antihistamines/antiasthmatics, cardiovascular, antivirals, antidiabetics, antifungals, and proton pump inhibitor areas, as well as support services, such as diagnostic clinics, educational seminars, and digital tools to help patients better manage their health. It provides it medicines in the form of oral solid doses, injectables, complex dosage forms, and APIs to retail and pharmacy establishments, wholesalers and distributors, payers, insurers and governments, and institutions. The company distributes its products through pharmaceutical wholesalers/distributors, pharmaceutical retailers, institutional pharmacies, mail-order and e-commerce pharmacies, and specialty pharmacies. It sells its products under the Lyrica, Lipitor, Creon, Influvac, Wixela Inhub, EpiPen auto-injector, Fraxiparine, and Yupelri; Norvasc and Viagra; AMITIZA, Lipacreon, and Effexor; and Celebrex and ARV names, as well as glargine and SEMGLEE names. The company has collaboration and licensing agreements with Revance Therapeutics, Inc.; and Momenta Pharmaceuticals, Inc. Viatris Inc. was founded in 1961 and is headquartered in Canonsburg, Pennsylvania.
Read More

Today's Range

Now: $11.16
Low: $11.05
High: $11.26

50 Day Range

MA: $12.16
Low: $11.32
High: $13.53

2 Week Range

Now: $11.16
Low: $8.74
High: $13.62

Volume

3,925,684 shs

Average Volume

9,638,309 shs

Market Capitalization

$13.39 billion

P/E Ratio

279.00

Dividend Yield

4.24%

Beta

1.13